Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Voodoo who wrote (2056)	1/27/1998 9:14:00 AM
From: Dauntless	Read Replies (2) \| Respond to of 7041

Dr. Voodoo - can you, as a chemist, offer an opinion? You wrote: >>As I said before and you have been kind enough to point out is that it is important to understand important details, like HOW something is measured.<< We can discuss the fine details & ramifications of the 1981 valid study until the cows come home. I would, however, appreciate a simple answer to a specific question. As a professional chemist, have you seen enough to at least comment on the validity of the study used by Asensio in his Jan. 15th report to attack Zonagen? It is my intent to provide complete documentation of the very materials used by Asensio to issue his reports - which are clearly an attempt to manipulate the stock price of a company in which he took a short position before beginning his campaign. The Jan. 15 report was titled: >>Zonagen's Vasomax fast-acting claims proven false and fraudulent.<< Now it turns out that just a little research reveals that the study was useless - scientifically invalid & never intended as anything but a progress report on the development of an measurement technique. I will prove that Asencio did this with the lawsuit filed by Dr. Bohgal and did it again with the patent application - each of which was used either in part, or out of context to attack the company. There definitely should be a class action lawsuit and probably an SEC investigation - but not of Zonagen.